Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Roche

Tamiflu drop slows revenue growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche 2Q10

2Q10 Revenues: $11.2 billion (flat)

YTD Revenues: $22.8 billion (+7%)

YTD Earnings: $5.1 billion (+43%)

Comments: Pharma sales were down 2% in 2Q10 to $8.7 billion, and were up 6% to $17.9 billion in 1H10. Half-year revenues were driven by Avastin ($3.1 billion), Rituxan ($3.1 billion) and Herceptin ($2.6 billion). The U.S. market accounted for 38% of pharma revenues. As expected, Tamiflu revenues dropped significantly after the previous year’s H1N1 flu-related stockpiling efforts. Avastin sales may pull back, following a vote by an FDA advisory committee recommending against use in a key breast cancer indication. Lucentis sales rose 27% to $645 million, an RA treatment Actemra posted $143 million in 1H10 sales globally, as it continues to gain new regional markets. Pharma R&D expenses in 1H10 were flat at $3.7 billion. The diagnostics division posted sales growth of 7% to reach $4.9 billion during the half-year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters